Ashton Tweed Connection Vol. 4 No. 3

Featuring CEO Interview with Christopher J. Schaber, PhD, President and CEO, Soligenix, Inc.

Your Issue of Ashton Tweed Connection Vol. 4 No. 3 is Here!

Our Site

Contact us

Vol. 4

No. 3

Ashton Tweed can meet your specialized retained search & interim talent needs in the life sciences industry.

CEO Leadership Series: Christopher J. Schaber, PhD, President and CEO, Soligenix, Inc.

For Christopher J. Schaber, successfully helming Soligenix Inc. involves walking a tightrope between developing a roster of promising drugs and raising the funds to pay for it. Recently listed on NASDAQ, Soligenix is a late-stage biopharmaceutical…

Read More

Case Study: Accounting Pro & Biopharma Expert is Ideal

A small clinical stage biopharmaceutical company in the Northeast, which specializes in developing novel antibiotics to be effective against serious and life-threatening infections, was growing and needed extra financial support in the…

Blog: C onquering the Clinical Trial with Interim Help

In the life sciences industry, clinical trials can be both exciting and daunting to embark on. When approaching clinical trials your science is already down pat, so new professionals and expertise are often needed for the next phase of develop…

Don’t miss out
on top hiring news!

Ashton Tweed’s Weekly Digest email covers hiring, firing, & retiring news in the life sciences. Also, check out our:

Featured Candidates

Upcoming Events

Recent Editions

Subscribe Now!

Genentech, Novo, Regeneron make Fortune’s list of best places to work

Roche, Novo Nordisk and Regeneron represent the pharmaceutical industry in FORTUNE‘s annual “100 Best Companies to Work For” list in 2017. Google, Wegmans and Boston Consulting Group took the top three…

CRISPR Therapeutics Announces European Patent for CRISPR/Cas

CRISPR Therapeutics reports that the European Patent Office (EPO) has announced its intention to grant a patent broadly covering CRISPR’s in-licensed gene editing technology. The European patent application received many third…

Pharma’s most-valuable brands?

U.S. pharma brands jumped in value in Brand Finance’s annual report of the nation’s 500 most valuable brands, with the exception of Valeant Pharmaceuticals. Brand value is different from reputation, which is…

C4 and Alphabet’s Calico hook up on aging

Alphabet company Calico and biotech startup C4 Therapeutics (C4T) join forces to tackle age-related diseases including cancer. This collaboration will use C4T’s expertise to discover small molecule candidates. Calico will then…

Featured Event: Phorum Philly 2017

When: April 27, 2017
Where: Philadelphia, PA
Digitizing the Enterprise – The Future is Now
Technology moves at an exponential pace and traditional organizations do not. True leaders cannot get left behind the digital curve.

Read More

After being pushed out of FDA role, Califf becomes chair of research group

Former FDA commissioner Robert Califf, who will likely be replaced by Scott Gottlieb as the new commissioner, has become the chair of the newly formed nonprofit called People-Centered Research…

After being pushed out of FDA role, Califf becomes chair of research group

Witty turns over the reins after 9 years at the GSK helm

GlaxoSmithKline CEO Andrew Witty has stepped down, passing the role to successor Emma Walmsley. This transition marks the end of his 9-year tenure at the company. Witty wasn’t afraid to take chances as a leader…

Witty turns over the reins after 9 years at the GSK helm

About Ashton Tweed, Ltd.

At the very core of Ashton Tweed’s talent-acquisition and talent-placement business is a robust professional force of highly experienced life sciences industry experts. These uniquely talented professionals are deployed throughout Ashton Tweed’s diverse range of service offerings to solve our clients’ human capital and management needs.